Biogen annual free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biogen Free Cash Flow (FCF) History (BIIB)
Biogen reported $2.05B in free cash flow for fiscal 2025, a decrease of 24.65% from the previous fiscal year, with a free cash flow margin of 20.73%.
View full Biogen company overviewBiogen free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.05B | −$671.0M | −24.65% | +20.73% |
| 2024 | 2024-12-31 | $2.72B | $1.45B | +114.28% | +28.13% |
| 2023 | 2023-12-31 | $1.27B | $126.2M | +11.03% | +12.91% |
| 2022 | 2022-12-31 | $1.14B | −$2.24B | −66.17% | +11.25% |
| 2021 | 2021-12-31 | $3.38B | −$423.2M | −11.12% | +30.79% |
| 2020 | 2020-12-31 | $3.81B | −$2.76B | −42.03% | +28.30% |
| 2019 | 2019-12-31 | $6.56B | $1.15B | +21.17% | +45.65% |
| 2018 | 2018-12-31 | $5.42B | $1.73B | +47.06% | +40.27% |
| 2017 | 2017-12-31 | $3.68B | −$287.5M | −7.24% | +30.01% |
| 2016 | 2016-12-31 | $3.97B | $694.7M | +21.20% | +34.69% |
| 2015 | 2015-12-31 | $3.28B | $622.1M | +23.44% | +30.44% |
| 2014 | 2014-12-31 | $2.65B | $555.5M | +26.47% | +27.35% |
| 2013 | 2013-12-31 | $2.10B | $473.5M | +29.13% | +30.28% |
| 2012 | 2012-12-31 | $1.63B | $105.6M | +6.95% | +29.46% |
| 2011 | 2011-12-31 | $1.52B | $68.1M | +4.69% | +30.10% |
| 2010 | 2010-12-31 | $1.45B | $542.4M | +59.65% | +30.78% |
| 2009 | 2009-12-31 | $909.3M | −$377.2M | −29.32% | +20.77% |
| 2008 | 2008-12-31 | $1.29B | $551.8M | +75.12% | +31.40% |
| 2007 | 2007-12-31 | $734.6M | — | — | +23.16% |
Biogen quarterly free cash flow
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $308.0M | $173.7M | +129.34% | +11.26% |
| Q1 2026 | 2026-03-31 | $594.3M | $372.1M | +167.46% | +23.98% |
| Q4 2025 | 2025-12-31 | $468.0M | −$253.6M | −35.14% | +20.53% |
| Q3 2025 | 2025-09-30 | $1.23B | $325.7M | +36.16% | +48.38% |
| Q2 2025 | 2025-06-30 | $134.3M | −$458.0M | −77.33% | +5.08% |
| Q1 2025 | 2025-03-31 | $222.2M | −$285.1M | −56.20% | +9.14% |
| Q4 2024 | 2024-12-31 | $721.6M | $774.3M | — | +29.40% |
| Q3 2024 | 2024-09-30 | $900.6M | $382.4M | +73.79% | +36.52% |
| Q2 2024 | 2024-06-30 | $592.3M | $176.3M | +42.38% | +24.03% |
| Q1 2024 | 2024-03-31 | $507.3M | $118.6M | +30.51% | +22.15% |
| Q4 2023 | 2023-12-31 | −$52.7M | $208.7M | — | −2.21% |
| Q3 2023 | 2023-09-30 | $518.2M | −$83.7M | −13.91% | +20.48% |
| Q2 2023 | 2023-06-30 | $416.0M | −$283.6M | −40.54% | +16.94% |
| Q1 2023 | 2023-03-31 | $388.7M | $284.8M | +274.11% | +15.78% |
| Q4 2022 | 2022-12-31 | −$261.4M | −$1.05B | — | −10.28% |
| Q3 2022 | 2022-09-30 | $601.9M | −$161.4M | −21.15% | +23.99% |
| Q2 2022 | 2022-06-30 | $699.6M | −$455.8M | −39.45% | +27.02% |
| Q1 2022 | 2022-03-31 | $103.9M | −$572.5M | −84.64% | +4.10% |
| Q4 2021 | 2021-12-31 | $786.7M | $1.24B | — | +28.78% |
| Q3 2021 | 2021-09-30 | $763.3M | −$333.7M | −30.42% | +27.47% |
| Q2 2021 | 2021-06-30 | $1.16B | −$688.1M | −37.33% | +41.64% |
| Q1 2021 | 2021-03-31 | $676.4M | −$641.2M | −48.66% | +25.11% |
| Q4 2020 | 2020-12-31 | −$453.1M | −$2.30B | — | −15.88% |
| Q3 2020 | 2020-09-30 | $1.10B | −$507.8M | −31.64% | +32.49% |
| Q2 2020 | 2020-06-30 | $1.84B | $66.4M | +3.74% | +50.07% |
| Q1 2020 | 2020-03-31 | $1.32B | −$14.8M | −1.11% | +37.28% |
| Q4 2019 | 2019-12-31 | $1.85B | $180.3M | +10.80% | +50.39% |
| Q3 2019 | 2019-09-30 | $1.60B | $32.1M | +2.04% | +44.58% |
| Q2 2019 | 2019-06-30 | $1.78B | $864.6M | +94.75% | +49.14% |
| Q1 2019 | 2019-03-31 | $1.33B | $70.0M | +5.54% | +38.18% |
| Q4 2018 | 2018-12-31 | $1.67B | $381.8M | +29.65% | +47.34% |
| Q3 2018 | 2018-09-30 | $1.57B | $173.5M | +12.40% | +45.73% |
| Q2 2018 | 2018-06-30 | $912.5M | −$59.0M | −6.07% | +27.19% |
| Q1 2018 | 2018-03-31 | $1.26B | $1.24B | +4909.52% | +40.32% |
| Q4 2017 | 2017-12-31 | $1.29B | −$112.1M | −8.01% | +38.94% |
| Q3 2017 | 2017-09-30 | $1.40B | $578.2M | +70.43% | +45.46% |
| Q2 2017 | 2017-06-30 | $971.5M | $110.1M | +12.78% | +31.56% |
| Q1 2017 | 2017-03-31 | $25.2M | −$863.7M | −97.17% | +0.90% |
| Q4 2016 | 2016-12-31 | $1.40B | $342.2M | +32.36% | +48.74% |
| Q3 2016 | 2016-09-30 | $821.0M | $154.8M | +23.24% | +27.78% |
| Q2 2016 | 2016-06-30 | $861.4M | −$56.0M | −6.10% | +29.76% |
| Q1 2016 | 2016-03-31 | $888.9M | $253.7M | +39.94% | +32.60% |
| Q4 2015 | 2015-12-31 | $1.06B | $231.7M | +28.05% | +37.25% |
| Q3 2015 | 2015-09-30 | $666.2M | −$185.3M | −21.76% | +23.98% |
| Q2 2015 | 2015-06-30 | $917.4M | −$9.2M | −0.99% | +35.40% |
| Q1 2015 | 2015-03-31 | $635.2M | $584.9M | +1162.32% | +24.86% |
| Q4 2014 | 2014-12-31 | $825.9M | $35.5M | +4.50% | +31.28% |
| Q3 2014 | 2014-09-30 | $851.5M | $259.8M | +43.90% | +33.90% |
| Q2 2014 | 2014-06-30 | $926.6M | $355.5M | +62.26% | +38.27% |
| Q1 2014 | 2014-03-31 | $50.3M | −$95.3M | −65.45% | +2.36% |
| Q4 2013 | 2013-12-31 | $790.4M | $351.5M | +80.09% | +40.20% |
| Q3 2013 | 2013-09-30 | $591.7M | $108.0M | +22.33% | +32.37% |
| Q2 2013 | 2013-06-30 | $571.1M | $8.4M | +1.49% | +33.13% |
| Q1 2013 | 2013-03-31 | $145.7M | $5.6M | +3.98% | +10.29% |
| Q4 2012 | 2012-12-31 | $438.9M | $35.3M | +8.76% | +30.95% |
| Q3 2012 | 2012-09-30 | $483.7M | −$35.5M | −6.83% | +34.91% |
| Q2 2012 | 2012-06-30 | $562.7M | $187.1M | +49.82% | +39.60% |
| Q1 2012 | 2012-03-31 | $140.1M | −$81.4M | −36.74% | +10.84% |
| Q4 2011 | 2011-12-31 | $403.5M | $21.3M | +5.58% | +30.42% |
| Q3 2011 | 2011-09-30 | $519.2M | $129.9M | +33.37% | +39.63% |
| Q2 2011 | 2011-06-30 | $375.6M | −$5.8M | −1.53% | +31.08% |
| Q1 2011 | 2011-03-31 | $221.4M | −$77.3M | −25.86% | +18.40% |
| Q4 2010 | 2010-12-31 | $382.2M | $158.4M | +70.77% | +31.36% |
| Q3 2010 | 2010-09-30 | $389.3M | $161.4M | +70.85% | +33.11% |
| Q2 2010 | 2010-06-30 | $381.4M | $187.6M | +96.74% | +31.45% |
| Q1 2010 | 2010-03-31 | $298.7M | $35.0M | +13.26% | +26.94% |
| Q4 2009 | 2009-12-31 | $223.8M | — | — | +19.86% |
| Q3 2009 | 2009-09-30 | $227.8M | −$219.5M | −49.06% | +20.33% |
| Q2 2009 | 2009-06-30 | $193.9M | — | — | +17.73% |
| Q1 2009 | 2009-03-31 | $263.7M | — | — | +25.44% |
| Q3 2008 | 2008-09-30 | $447.3M | — | — | +40.93% |
Biogen free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $3.81B to $2.05B, a compound annual decline of 11.63%. Biogen's latest reported quarter, Q2 2026, generated $308.0M in free cash flow, an increase of 129.34% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Biogen source filings ↗Community posts
Biogen and Eisai win Japanese approval for Leqembi injection pen
Biogen ($BIIB) and Eisai received Japanese approval for Leqembi Pen, a subcutaneous formulation of their treatment for early Alzheimer’s disease. The regimen uses two pens totaling 500 milligrams once weekly, offering an alternative to intr ...
